CERo Therapeutics Holdings, Inc.
CERO
$0.8899
-$0.0579-6.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.55M | 10.43M | 8.06M | 6.82M | 4.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.20M | 15.22M | 12.36M | 9.62M | 7.51M |
| Operating Income | -16.20M | -15.22M | -12.36M | -9.62M | -7.51M |
| Income Before Tax | -8.30M | -10.24M | -7.36M | -7.01M | -7.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.30 | -10.24 | -7.36 | -7.01 | -7.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.30M | -10.24M | -7.36M | -7.01M | -7.15M |
| EBIT | -16.20M | -15.22M | -12.36M | -9.62M | -7.51M |
| EBITDA | -15.76M | -14.77M | -11.90M | -9.16M | -7.05M |
| EPS Basic | -40.13 | -58.68 | -65.05 | -73.02 | -85.14 |
| Normalized Basic EPS | -30.91 | -42.31 | -46.29 | -49.54 | -53.29 |
| EPS Diluted | -40.13 | -58.68 | -65.05 | -73.02 | -85.14 |
| Normalized Diluted EPS | -30.91 | -42.31 | -46.29 | -49.54 | -53.29 |
| Average Basic Shares Outstanding | 2.02M | 838.00K | 431.90K | 360.50K | 334.40K |
| Average Diluted Shares Outstanding | 2.02M | 838.00K | 431.90K | 360.50K | 334.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |